Hypertriglyceridemia is a common disorder in which the triglyceride levels in the body increase. It is often caused or exacerbated by uncontrolled diabetes mellitus, obesity, and sedentary habits, all of which are more prevalent in industrialized societies than in developing nations. This rising levels of triglyceride are majorly associated with predisposing cardiovascular diseases and atherosclerosis, even in the absence of high cholesterol levels. Hypertriglyceridemia also causes pancreatitis, atherosclerosis, and other cardiovascular diseases. Currently, the advancements in treatment of hypertriglyceridemia are helping in recovering the triglyceride levels in the human body. Severe hypertriglyceridemia means your triglycerides are 500 mg/dL or higher. People with severe hypertriglyceridemia face an increased risk of acute pancreatitis. This is a pancreatic inflammation that needs medical attention. Most people with hypertriglyceridemia have no symptoms. People with severe hyperglyceridemia may develop xanthomas. These are skin bumps that form when lipids build up under your skin. The xanthomas usually appear around your eyelids. But they may also appear on your knees, elbows or palms of your hands. Genetics- increased triglyceride levels in the blood may be associated with certain genetic diseases or disorders, such as familial combined hyperlipidemia.

Market Dynamics

The ongoing research & development of developing novel drugs is expected to propel the global hypertriglyceridemia market growth during the forecast period. Further, growing prevalence of cardiovascular diseases such as atherosclerosis, hypertension, and coronary heart disease and sedentary lifestyle is also expected to boost the global hypertriglyceridemia therapeutics market over the forecast period. For instance, in February 2020, Esperion Therapeutics, Inc., a pharmaceutical company that develops and commercializes once-daily, oral and low-density lipoprotein cholesterol-lowering therapies, announced that the U.S. Food and Drug Administration (FDA) approved NEXLETOL (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering medicine. NEXLETOL is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C. The effect of NEXLETOL on cardiovascular morbidity and mortality has not been determined. NEXLETOL is a first-in-class ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C by inhibition of cholesterol synthesis in the liver.

Key features of the study:

• This report provides in-depth analysis of the global hypertriglyceridemia therapeutics market, and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global hypertriglyceridemia therapeutics market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study are Sanofi, GSK, plc., Biocon, Novo Nordisk A/S, Tonghua Dongbao Pharmaceutical Co., Ltd., Oramed, AbbVie Inc., Merck & Co., Inc. WOCKHARDT, Pfizer Inc., Julphar, Eli Lilly and Company, Bristol-Myers Squibb Company, ADOCIA, Hikma Pharmaceuticals PLC, Lupin, Zydus Pharmaceuticals, Inc., Glenmark Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC., Aurobindo Pharma, and Accord Healthcare.
• Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global hypertriglyceridemia therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hypertriglyceridemia therapeutics market

Detailed Segmentation:

• Global Hypertriglyceridemia Therapeutics Market, By Type:
  • Primary
  • Secondary
• Global Hypertriglyceridemia Therapeutics Market By Drug Class:
  • Statins
  • Fibrates
  • Omega-3 Fatty Acids
  • HMG-CoA Reductase inhibitors
  • Niacin
• Global Hypertriglyceridemia Therapeutics Market By Distribution Channel:
  • Retail Pharmacy
  • Hospitals Pharmacy
  • Online Pharmacy
  • Others
• Global Hypertriglyceridemia Therapeutics Market, By Region:
  • North America
    
    • U.S.
    • Canada
  • Latin America
    
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    
    • South Africa
    • Central Africa
    • North Africa
• Company Profiles
  • Sanofi
  • GSK, plc.
  • Biocon
  • Novo Nordisk A/S
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • Oramed
  • AbbVie Inc.
  • Merck & Co., Inc.
  • WOCKHARDT
  • Pfizer Inc.
  • Julphar
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • ADOCIA
  • Hikma Pharmaceuticals PLC
  • Lupin
  • Zydus Pharmaceuticals, Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Amneal Pharmaceuticals LLC.
  • Aurobindo Pharma
  • Accord Healthcare